ceftaroline

AstraZeneca in a transaction beyond just ceftaroline.

Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011

First of all, with ceftaroline, the major is actually the combination right now with the

Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011

Forest licensed Novexel, a French biotech company, the rights for North America for NXL 104, a beta-lactamase inhibitor for use in combination with ceftaroline.

Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011

NXL 104 is a compound that inhibits several classes of bacterial enzymes called beta-lactamase that break down and activate beta-lactam antibiotics such as: Cephalosporin, a class to which ceftaroline belongs; penicillins; and carbapenems, making the pathogens producing these enzymes resistant to these antibiotics.

Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011

In this transaction with AstraZeneca, which was executed immediately following AstraZeneca acquisition of Novexel, we acquired additional rights to NXL 104, covering not only the combination with ceftaroline but also adding U.S. right to the combination of ceftazidime and NXL 104, as well as other future possible combination with other antibiotics.

Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011

Next up, with our anti-infective pipeline, for October 2009, we were very pleased to receive from the FDA news of approval of Teflaro ceftaroline.

Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011

Both are other stage programs, and we've partnered with the AstraZeneca for the co-development and commercialization of ceftaroline, and ceftaroline/104 outside the U.S.

Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011

I think that these are really two well-suited indication for ceftaroline.

Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011

So our anti-infective product portfolio antibiotics with our active predominantly against both gram-positive pathogens, like ceftaroline and ceftaroline NXL 104 and also products active against gram-negative pathogens like ceftazidime and with NXL 104, addressing virtually the entire spectrum of clinical relevant bacterial pathogens.

Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011

We have a very active product especially on the gram-positive side, and we have good activity on the gram-negative but with combination with 104, actually will make the gram-negative side of ceftaroline much, much stronger.

Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011